The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Colcrys Approval Triggers Questions

Colcrys Approval Triggers Questions

May 1, 2010 • By Kurt Ullman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The Food, Drug and Cosmetics Act of 1938 and the 1962 amendments to that law charged the Food and Drug Administration (FDA) with approving drugs that are safe and effective. Colchicine is one of many medications that was unapproved and was widely available before the act took effect. In June of 2006, the FDA and its Center for Drug Evaluation and Research (CDER) undertook the Unapproved Drugs Initiative to bring more of these older drugs into compliance.

You Might Also Like
  • The Law of Unintended Consequences Rears Its Head
  • FDA Enforcement Against Injectable Colchicine
  • Generic Colchicine Approved for Gout Prophylaxis
Explore This Issue
May 2010
Also By This Author
  • ICD-10 Adoption Brings Major Changes to Practices

“Our mission is to ensure that safe and effective drugs are available,” writes Michael Levy, Esq., director of CDER’s Division of New Drugs and Labeling Compliance, in an e-mail response to questions. “Since the initiative began, marketers of unapproved drugs are on notice that addressing risks from unapproved drugs is a high priority, and that the agency plans to ensure all products on the prescription drug market comply with current requirements for safety and efficacy.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The approval pathways a pharmaceutical company takes to gain approval to market existing unapproved drugs are the same as for new drugs. Generally, all new prescription drugs must go through the New Drug Approval (NDA) process before being legally marketed. Since the initiative started, over 500 unapproved products have been removed from the market and more than 70 older, unapproved drugs have earned approval.

URL Pharma and the Rheumatology Market

URL Pharma, based in Philadelphia, decided to focus on colchicine, among other products. “We looked at the universe of unapproved drugs, searching for medications presenting safety risks or where we had a chance to improve efficacy,” says Richard Roberts, MD, president, chair, and CEO of URL Pharma. “As a physician, I was shocked that colchicine, with all of the toxicities taught [to] every doctor since medical school, was not an approved medication.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In July 2009, the FDA granted URL Pharma approval to market a form of colchicine for acute gout and familial Mediterranean fever (FMF). An indication for gout flare prophylaxis followed in October. They were given three-year marketing exclusivity for gout and a seven-year term for FMF as an orphan drug. The branded medication called Colcrys sells for about $5.00 a tablet, or roughly 50 times the cost of the unapproved version.

The ACR, responding to member concerns about the new pricing, acted quickly, first consulting with the FDA to discuss its concerns, and then contacting URL Pharma. (A summary of the ACR’s discussion with the FDA is available online at www.rheumatology.org/advocacy/colchicine_ fda.pdf.) The ACR worked closely with URL Pharma on changes to its Colcrys patient assistance program (PAP), resulting in wider coverage. The ACR has also obtained a list of other colchicine makers and has encouraged them to go through the approval process for other indications.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Drug Updates, Education & Training, Practice Management, Quality Assurance/Improvement, Safety Tagged With: CDER, Colchicine, Drugs, FDA, Gout, Industry, Patients, Unapproved Drugs Initiative, URL PharmaIssue: May 2010

You Might Also Like:
  • The Law of Unintended Consequences Rears Its Head
  • FDA Enforcement Against Injectable Colchicine
  • Generic Colchicine Approved for Gout Prophylaxis
  • Recro Pharma’s Non-Opioid Pain Shot Fails to Get Approval from FDA

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)